Objectives: To determine outcomes in local-regional control and overall survival in patients with squamous locally advanced cancer of the oral cavity, based on intention-to-treat with neoadjuvant chemotherapy followed by surgery or radiation therapy. Methods: Two hundred and four out of 1,089 patients analyzed met the defined criteria. All had squamous cell carcinomas of the oral cavity in stage III or in nonmetastatic stage IV and were selected for surgery or radiation therapy (if located in the tonsils or in the base of the tongue). Chemotherapy was based on cisplatin 120 mg/m2 i.v. day 1 plus bleomycin 20 mg/m2 days 1–5 in continuous i.v. perfusion or plus 5-fluorouracil 1,000 mg/m2 days 1–5 in continuous i.v. perfusion. A total of 418 cycles were given to 204 patients (mean 2.049 per patient). Definitive surgery (n = 73; plus adjuvant radiation therapy) or definitive radiation therapy (n = 131) was performed. Results: One hundred thirty-five out of 204 (66%) patients were chemotherapy responders, 16% complete and 50% partial. One hundred ninety-four patients (95%) completed 2 courses of chemotherapy. After neoadjuvant chemotherapy, 34 out of 46 patients considered inoperable initially (74%) obtained a disease-free status with surgery. Eighty-three percent of surgical patients obtained a disease-free status (initial tumor control) versus 72% of radiation therapy patients. Disease-free survival rates at 5 years were 26 and 22%, respectively. A better prognosis was observed in stage III over IV (p = 0.02); primary tumor in the retromolar trigone, palate or buccal mucosa over tongue, tonsil or floor of the mouth (p = 0.0085); negative cervical nodes over positive (p = 0.0186); responders to chemotherapy over nonresponders (p = 0.0003); and adjuvant postsurgical radiation therapy (p = 0.0013). Causes of death were relapses in local area (86%), regional nodes (10.5%) or distant metastases (3.5%). Eleven patients (5%) died of a second primary. The main toxic effects were vomiting in 9% of patients and hemolytic-uremic syndrome in 3% of the patients treated with bleomycin. Conclusions: In locally advanced squamous cell carcinoma of the oral cavity, neoadjuvant chemotherapy induces a high response rate that may facilitate definitive surgery or radiotherapy. In this study, patients have an acceptable long-term survival.

Keywords:
Oral cavity cancer, Neoadjuvant chemotherapy, Radiation therapy, Cisplatin, Bleomycin, 5-Fluorouracil, Tegafur, Carboplatin
1.
Spiro RH, Alfonso AE, Hollon WF: Cervical node metastasis from epidermoid carcinoma of the oral cavity and oropharynx. Am J Surg 1974;128:562–567.
2.
Pignon PJ, Bourthis J, Domenge C, Designé L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of an updated individual data. MACH-NH Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949–955.
3.
Vikram B: Adjuvant therapy in head and neck cancer. CA Cancer J Clin 1998;48:199–209.
4.
Cooper JS, Farnan NC, Asbell SO, et al: Recursive partitioning analysis of 2105 patients treated in Radiation Therapy Oncology Group studies of head and neck cancer. Cancer 1996;77:1905–1911.
5.
Harari PM: Why has induction chemotherapy for advanced head and neck cancer become a United States Community standard of practice? J Clin Oncol 1997;15:2050–2055.
6.
Vokes EE, Athanaisiadis I: Chemotherapy for squamous cell carcinoma of head and neck: The future is now. Ann Oncol 1996;7:15–19.
7.
Jacobs C, Makuch R: Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: A subset analysis of Head and Neck Contracts Program. J Clin Oncol 1990;8:838–847.
8.
Schuller DE, Metch B, Stein DW, et al: Preoperative chemotherapy in advanced resectable head and neck cancer: Final report of Southwest Oncology Group. Laryngoscope 1988;98:1205–1211.
9.
Grau JJ, Estapé J, Cuchi MA, Firvida JL, Blanch JL, Ascaso C: Calcium supplementation and ototoxicity in patients receiving cisplatin. Br J Clin Pharmacol 1996;43:233–235.
10.
Jacobs C: Adjuvant and neoadjuvant treatment of head and neck cancers. Semin Oncol 1991;18:504–514.
11.
Cognetti F, Pinnaro P, Ruggeri EM, et al: Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cancer. J Clin Oncol 1989;7:829–837.
12.
Hill BT, Price LA, MacRae K: Importance of primary site in assessing chemotherapy response and 7-year survival data in advanced squamous-cell carcinomas of head and neck treated with initial combination chemotherapy without cisplatin. J Clin Oncol 1986;4:1340–1347.
13.
Marks SC: Surgical management of head and neck cancer. Hematol Oncol Clin North Am 1999;13:655–673.
14.
Goepfert H: Squamous cell carcinoma of the head and neck: Past progress and future promise. CA Cancer J Clin 1998;48:195–197.
15.
American Joint Committee on Cancer: Manual for Staging of Cancer, ed 3. Philadelphia, Lippincott, 1988.
16.
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207–214.
17.
Peto P, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observations on each patient. Br J Cancer 1976;34:585–612.
18.
Carew JF, Shah JP: Advances in multimodality therapy for laryngeal cancer. CA Cancer J Clin 1998;48:211–228.
19.
Mendenhall WM, Stringer SP, Amdur RJ, Hinerman RW, Moore-Higgs GJ, Cassisi NJ: Is radiation therapy a preferred alternative to surgery for squamous cell carcinoma of the base of tongue? J Clin Oncol 2000;18:35–42.
20.
Giralt JL, Gonzalez J, del Campo JM, et al: Preoperative induction chemotherapy followed by concurrent chemoradiotherapy in advanced carcinoma of the oral cavity and oropharynx. Cancer 2000;89:839–945.
21.
Sikic BI, Collins JM, Mimneugh EG, Gram TE: Improved therapeutic index of bleomycin when administered by continuous infusion in mice. Cancer Treat Rep 1978;62:2011–2017.
22.
Ensley J, Jacobs J, Weaver A, et al: Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of head and neck. Cancer 1984;54:811–814.
23.
Adelstein DJ: Induction chemotherapy in head and neck cancer. Hematol Oncol Clin North Am 1991;5:667–686.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.